Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Epizyme, Inc. (NASDAQ: EPZM).

Full DD Report for EPZM

You must become a subscriber to view this report.


Recent News from (NASDAQ: EPZM)

Epizyme working to lift partial clinical hold on tazemetostat
Epizyme ( EPZM ) reports that it has submitted responses to the FDA regarding the partial clinical hold (enrollment suspended but study participants may still receive treatment) on lead candidate tazemetostat. More news on: Epizyme, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:34
Epizyme Should Pop When Tazemetostat Hold Clears
Epizyme ( EPZM ) is a small-cap, clinical stage biotechnology company specializing in cancer treatments based on epigenetics. Tazemetostat is an orally administered, first-in-class, small molecule EZH2 inhibitor, for the treatment of multiple types of lymphoma and other genetically defined t...
Source: SeekingAlpha
Date: August, 23 2018 10:33
Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blucora, Inc. (NASDAQ:BCOR), Sapiens International Corporation N.V. (NASD...
Source: GlobeNewswire
Date: August, 20 2018 07:30
Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats
Stocks in News: EPZM, MDXG Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES Discussion : Epizyme ( EPZM ) announced the termination of the development program of tazemetostat in diffuse large B-cell lymphoma (‘DLBCL). Main reaso...
Source: SeekingAlpha
Date: August, 05 2018 03:53
Biotech Analysis Central Pharma News: Teva's U.S. Erosion, Denali's Preliminary Results, Epizyme's Trial Shutdown
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Teva Dips As U.S. Generic Sales Continue To Drop News: Recently, Teva Pharmaceuticals ( TEVA ) announced its Q2 earnings. It reported adjusted inco...
Source: SeekingAlpha
Date: August, 03 2018 00:16
Epizyme's (EPZM) CEO Rob Bazemore on Q2 2018 Results - Earnings Call Transcript
Epizyme Inc. (EPZM) Q2 2018 Earnings Conference Call August 2, 2018 8:30 AM ET Executives Jason Fredette – Vice President, Investor Relations Rob Bazemore – Chief Executive Officer Susan Graf – Chief Business Officer Analysts Michael Yee – Jeffer...
Source: SeekingAlpha
Date: August, 02 2018 14:07
Midday Gainers / Losers (08/02/2018)
Gainers: IHT +76% . WIFI +34% . MOC +27% . QTRH +27% . DXCM +26% . STAA +23% . FOXF +21% . ESIO +21% . RFP +19% . RUBI +19% . More news on: Innsuites Hospitality Trust, Boingo Wireless, Command Security Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 02 2018 12:35
Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES
Epizyme (NASDAQ: EPZM ) slumps  8%  premarket on light volume despite is Q2 beat. The culprits appear to be its announcement that it is terminating development of tazemetostat in diffuse large B-cell lymphoma (DLBCL) due to lack of efficacy and the extended timeline for the filin...
Source: SeekingAlpha
Date: August, 02 2018 08:25
Epizyme beats by $0.09, beats on revenue
Epizyme (NASDAQ: EPZM ): Q2 EPS of -$0.42 beats by $0.09 . More news on: Epizyme, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 02 2018 07:13
Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates
Conference Call to be Held Today at 8:30 a.m. ET Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today reported financial results for the second quarter of 2018 and provided key business updates. “In the second quarter, we pre...
Source: Business Wire
Date: August, 02 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.8510.1510.259.70407,225
2018-05-1716.2516.9517.3516.201,119,532
2017-02-0210.3011.2511.7010.05852,212
2017-02-0110.5510.3010.8010.15199,177
2017-01-319.6510.5010.609.60255,771

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1045,657128,22835.6061Short
2018-12-0766,671135,84449.0791Short
2018-12-0659,362139,69242.4949Short
2018-12-04126,014214,80758.6638Short
2018-12-03138,219202,60968.2196Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EPZM.


About Epizyme, Inc. (NASDAQ: EPZM)

Logo for Epizyme, Inc. (NASDAQ: EPZM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EPZM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 05 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 05 2018
      Automatic shelf registration statement of securities of well-known seasoned issuers
      Filing Type: S-3ASRFiling Source: edgar
      Filing Date: April, 05 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 03 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 03 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: EPZM)

      Daily Technical Chart for (NASDAQ: EPZM)


      Stay tuned for daily updates and more on (NASDAQ: EPZM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EPZM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EPZM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EPZM and does not buy, sell, or trade any shares of EPZM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/